TY - JOUR
T1 - Dissecting the allosteric FXR modulation
T2 - A chemical biology approach using guggulsterone as a chemical tool
AU - Passeri, Daniela
AU - Carotti, Andrea
AU - Pittol, Jose M.Ramos
AU - Ciaccioli, Gianmario
AU - Pellicciari, Roberto
AU - Van Mil, Saskia W.C.
AU - Gioiello, Antimo
N1 - Funding Information:
This work could not have been undertaken without the financial support from TES Pharma (Perugia, Italy) and Intercept Pharmaceuticals (New York, USA). This work was also supported by FP7 Marie Curie Actions IAPP (FXR-IBD, 611979). NVIDIA Corporation is gratefully acknowledged for the donation of the GPU used to perform the molecular dynamics simulations. We also thank Nico Lansu and Noortje van den Dungen for the preparation of sequencing libraries at the Epigenomics facility, UMC Utrecht, and the Utrecht Sequencing Facility for providing sequencing service and data.
Publisher Copyright:
© 2019 The Royal Society of Chemistry.
PY - 2019
Y1 - 2019
N2 - Guggulsterone is a promiscuous ligand for endocrine and metabolic lipid receptors traditionally used to treat a number of diseases including diabesity, hyperlipidemia, atherosclerosis, and osteoarthritis. Although relatively weak, its activity at the farnesoid X receptor (FXR) is particularly intriguing as guggulsterone acts as an antagonist with a peculiar ability of gene selective modulation. We report here a chemical biology study with the aim to further characterize the biological action of guggulsterone at the FXR and to obtain further insights into the functional role played by noncanonical FXR binding pockets S2 and S3. Our results suggest that the FXR accessory pockets might act as potential targets for small molecules able to modulate the metabolic activation of the receptor without affecting the anti-inflammatory activity thus revealing a new approach for disclosing selective FXR modulators that might bypass potential side-effects from chronic treatments.
AB - Guggulsterone is a promiscuous ligand for endocrine and metabolic lipid receptors traditionally used to treat a number of diseases including diabesity, hyperlipidemia, atherosclerosis, and osteoarthritis. Although relatively weak, its activity at the farnesoid X receptor (FXR) is particularly intriguing as guggulsterone acts as an antagonist with a peculiar ability of gene selective modulation. We report here a chemical biology study with the aim to further characterize the biological action of guggulsterone at the FXR and to obtain further insights into the functional role played by noncanonical FXR binding pockets S2 and S3. Our results suggest that the FXR accessory pockets might act as potential targets for small molecules able to modulate the metabolic activation of the receptor without affecting the anti-inflammatory activity thus revealing a new approach for disclosing selective FXR modulators that might bypass potential side-effects from chronic treatments.
UR - http://www.scopus.com/inward/record.url?scp=85070720174&partnerID=8YFLogxK
U2 - 10.1039/c9md00264b
DO - 10.1039/c9md00264b
M3 - Article
AN - SCOPUS:85070720174
SN - 2040-2503
VL - 10
SP - 1412
EP - 1419
JO - MedChemComm
JF - MedChemComm
IS - 8
ER -